Do systematic reviews on pediatric topics need special methodological considerations?

被引:15
作者
Farid-Kapadia, Mufiza [1 ]
Askie, Lisa [2 ]
Hartling, Lisa [3 ]
Contopoulos-Ioannidis, Despina [4 ,5 ]
Bhutta, Zulfiqar A. [1 ]
Soll, Roger [6 ,7 ]
Moher, David [8 ]
Offringa, Martin [1 ]
机构
[1] Univ Toronto, Hosp Sick Children, Res Inst, Child Hlth Evaluat Sci, 555 Univ Ave, Toronto, ON M5G 1X8, Canada
[2] Univ Sydney, NHMRC Clin Trials Ctr, Systemat Reviews & Hlth Technol Assessment, Sydney, NSW, Australia
[3] Univ Alberta, Dept Pediat, Alberta Res Ctr Hlth Evidence, Edmonton, AB, Canada
[4] Stanford Univ, Dept Pediat, Div Infect Dis, Sch Med, Stanford, CA 94305 USA
[5] Metares Innovat Ctr Stanford METR, Stanford, CA USA
[6] Univ Vermont, Coll Med, Burlington, VT 05405 USA
[7] Cochrane Neonatal Review Grp, Burlington, VT USA
[8] Ottawa Hosp Res Inst, Ctr Practice Changing Res, Ottawa, ON, Canada
关键词
Systematic reviews; Pediatrics; Methods; Reporting guideline; MEDICAL INTERVENTIONS; SEARCH STRATEGIES; CLINICAL-TRIALS; CHILD HEALTH; METAANALYSES; OUTCOMES; QUALITY; PLACEBO; STILLBIRTHS; NUTRITION;
D O I
10.1186/s12887-017-0812-1
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Systematic reviews are key tools to enable decision making by healthcare providers and policymakers. Despite the availability of the evidence based Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA-2009 and PRISMA-P 2015) statements that were developed to improve the transparency and quality of reporting of systematic reviews, uncertainty on how to deal with pediatric-specific methodological challenges of systematic reviews impairs decision-making in child health. In this paper, we identify methodological challenges specific to the design, conduct and reporting of pediatric systematic reviews, and propose a process to address these challenges. Discussion: One fundamental decision at the outset of a systematic review is whether to focus on a pediatric population only, or to include both adult and pediatric populations. Both from the policy and patient care point of view, the appropriateness of interventions and comparators administered to pre-defined pediatric age subgroup is critical. Decisions need to be based on the biological plausibility of differences in treatment effects across the developmental trajectory in children. Synthesis of evidence from different trials is often impaired by the use of outcomes and measurement instruments that differ between trials and are neither relevant nor validated in the pediatric population. Other issues specific to pediatric systematic reviews include lack of pediatric-sensitive search strategies and inconsistent choices of pediatric age subgroups in meta-analyses. In addition to these methodological issues generic to all pediatric systematic reviews, special considerations are required for reviews of health care interventions' safety and efficacy in neonatology, global health, comparative effectiveness interventions and individual participant data meta-analyses. To date, there is no standard approach available to overcome this problem. We propose to develop a consensus-based checklist of essential items which researchers should consider when they are planning (PRISMA-PC-Protocol for Children) or reporting (PRISMA-C-reporting for Children) a pediatric systematic review. Summary: Available guidelines including PRISMA do not cover the complexity associated with the conduct and reporting of systematic reviews in the pediatric population; they require additional and modified standards for reporting items. Such guidance will facilitate the translation of knowledge from the literature to bedside care and policy, thereby enhancing delivery of care and improving child health outcomes.
引用
收藏
页数:11
相关论文
共 62 条
[1]   CLINICAL TRIALS OF DRUGS USED OFF-LABEL IN NEONATES: ETHICAL ISSUES AND ALTERNATIVE STUDY DESIGNS [J].
Amin, Sanjiv B. ;
McDermott, Michael P. ;
Shamoo, Adil E. .
ACCOUNTABILITY IN RESEARCH-POLICIES AND QUALITY ASSURANCE, 2008, 15 (03) :168-187
[2]  
[Anonymous], MILL DEV GOALS 2014
[3]  
[Anonymous], 2003, Cochrane Database Syst Rev
[4]  
[Anonymous], CONSORT EXTENSION CH
[5]  
[Anonymous], 2006, HEALTH RES POLICY SY, DOI DOI 10.1186/1478-4505-4-13
[6]  
[Anonymous], 2014, LANCET
[7]  
[Anonymous], COCHRANE DATABASE SY
[8]  
[Anonymous], ESS INT REPR MAT NEW
[9]  
[Anonymous], TRIALS S1
[10]  
[Anonymous], CMAJ OPEN